<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Supportive Therapy in Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Supportive Therapy in Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Поддерживающая терапия в онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">3034-2473</issn><issn publication-format="electronic">3034-3178</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69</article-id><article-id pub-id-type="doi">10.17650/3034-2473-2025-2-3-40-47</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Complications of carcinoid syndrome: diagnosis and treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Осложнения карциноидного синдрома: диагностика и лечение</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0211-9809</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanova</surname><given-names>Anastasiya K.</given-names></name><name xml:lang="ru"><surname>Иванова</surname><given-names>Анастасия Константиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D, PhD, Oncologist at the Division of Antitumor Drug Therapy (chemotherapy) No. 11, Head of the Division for Clinical Trial Management</p></bio><bio xml:lang="ru"><p>к.м.н., врач-онколог отделения противоопухолевой лекарственной терапии (химиотерапевтического) № 11, заведующая отделом организации клинических исследований</p></bio><email>oncolog.ivanova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0272-4240</contrib-id><name-alternatives><name xml:lang="en"><surname>Dinikin</surname><given-names>Mikhayl S.</given-names></name><name xml:lang="ru"><surname>Диникин</surname><given-names>Михаил С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>oncolog.ivanova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4447-9458</contrib-id><name-alternatives><name xml:lang="en"><surname>Orlova</surname><given-names>Rashida V.</given-names></name><name xml:lang="ru"><surname>Орлова</surname><given-names>Рашида Вахидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, DSc, Professor, Head of the Oncology Department of the Medical Faculty, Chief Specialist in Clinical Oncology and Rehabilitation</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой онкологии медицинского факультета, главный специалист по клинической онкологии и реабилитации</p></bio><email>oncolog.ivanova@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Saint Petersburg City Clinical Oncology Dispensary</institution></aff><aff><institution xml:lang="ru">СПб ГБУЗ «Городской клинический онкологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Saint Petersburg State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-12-25" publication-format="electronic"><day>25</day><month>12</month><year>2025</year></pub-date><volume>2</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>40</fpage><lpage>47</lpage><history><date date-type="received" iso-8601-date="2025-08-25"><day>25</day><month>08</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-09-18"><day>18</day><month>09</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Ivanova A.K., Dinikin M.S., Orlova R.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Иванова А.К., Диникин М.С., Орлова Р.В.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Ivanova A.K., Dinikin M.S., Orlova R.V.</copyright-holder><copyright-holder xml:lang="ru">Иванова А.К., Диникин М.С., Орлова Р.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://stio.abvpress.ru/jour/article/view/69">https://stio.abvpress.ru/jour/article/view/69</self-uri><abstract xml:lang="en"><p>Neuroendocrine neoplasms have heterogeneous morphological features and varying clinical manifestations, which in turn influences their therapeutic approach. Histologically, based on cell morphology, they can be divided into neuroendocrine tumors and neuroendocrine carcinomas. Clinically, they are subdivided into functioning (in the presence of a specific tumor syndrome) and nonfunctioning (in cases where only general, nonspecific symptoms are observed). One of the most common clinical manifestations of functioning neuroendocrine tumors is carcinoid syndrome, caused by the tumor’s secretion of multiple hormonal amines and peptides, primarily serotonin. In most cases, these tumors are relatively indolent. However, as the disease slowly progresses, patients may experience delayed complications such as carcinoid heart disease, mesenteric fibrosis, malnutrition, and vitamin deficiencies. Carcinoid syndrome can also rapidly worsen to a life-threatening complication known as a carcinoid crisis. Given the multifaceted and insidious nature of carcinoid syndrome, effective treatment relies on the indispensable role of a multidisciplinary team consisting of gastroenterologists, endocrinologists, radiologists, oncologists, nuclear medicine physicians, surgeons, cardiologists, and nutritionists.</p></abstract><trans-abstract xml:lang="ru"><p>Нейроэндокринные новообразования имеют гетерогенные морфологические особенности, различные клинические проявления, что влияет на терапевтический подход к ним. С гистологической точки зрения на основании морфологии клеток их можно разделить на нейроэндокринные опухоли и нейроэндокринные карциномы. С клинической точки зрения они подразделяются на функционирующие (при наличии специфического опухолевого синдрома) и нефункционирующие (в случаях, когда наблюдаются только общие, неспецифические симптомы). Одно из наиболее часто встречающихся клинических проявлений функционирующих нейроэндокринных опухолей – карциноидный синдром, вызванный секрецией опухолью множества гормональных аминов и пептидов, в основном серотонина. В большинстве случаев эти опухоли развиваются достаточно индолентно, однако по мере медленного прогрессирования заболевания у пациентов могут возникать отсроченные осложнения, такие как карциноидная болезнь сердца, мезентериальный фиброз, недостаточность питания и дефицит витаминов, а также течение карциноидного синдрома может резко ухудшиться до опасного для жизни осложнения, известного как карциноидный криз. С учетом многогранности и коварства течения карциноидного синдрома для эффективного его лечения необходима междисциплинарная команда, состоящая из гастроэнтерологов, эндокринологов, рентгенологов, онкологов, врачей ядерной медицины, хирургов, кардиологов и нутрициологов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>neuroendocrine tumor</kwd><kwd>carcinoid syndrome</kwd><kwd>carcinoid crisis</kwd><kwd>malnutrition</kwd><kwd>carcinoid heart disease</kwd><kwd>mesenteric fibrosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>нейроэндокринная опухоль</kwd><kwd>карциноидный синдром</kwd><kwd>карциноидный криз</kwd><kwd>недостаточность питания</kwd><kwd>карциноидная болезнь сердца</kwd><kwd>мезентериальный фиброз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Clement D., Ramage J., Srirajaskanthan R. Updateon pathophysiology, treatment, and complications of carcinoid syndrome. J Oncol 2020;2020:8341426. DOI: 10.1155/2020/8341426</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Halperin D.M., Shen C., Dasari A. et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis:Apopulation-based study. Lancet Oncol 2017;18:525–34. DOI: 10.1016/S1470-2045(17)30110-9</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Pavel M., Öberg K., Falconi M. et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844–60. DOI: 10.1016/j.annonc.2020.03.304</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Magi L., Rinzivillo M., Panzuto F. What Gastroenterologists Should Know about Carcinoid Syndrome. Gastroenterol. Insights 2022;13:127–38. DOI:10.3390/gastroent13010014</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Grozinsky-Glasberg S., Davar J., Hofland J. et al. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol 2022;34:13146. DOI: 10.1111/jne.13146</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Beaumont J.L., Cella D., Phan A.T. et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 2012;41:461–6. DOI: 10.1097/MPA.0b013e3182328045</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Condron M.E., Pommier S.J., Pommier R.F. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery 2016;159:358–65. DOI: 10.1016/j.surg.2015.05.036</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Maxwell J.E., Naraev B., Halperin D.M. et al. Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol 2022;29:3072–84.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Condron M.E., Jameson N.E., Limbach K.E. et al. A prospective study of the pathophysiology of carcinoid crisis. Surgery 2019;165:158–65.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kwon D.H., Paciorek A., Mulvey C.K. et al. Periprocedural management of patients undergoing liver resection or embolotherapy for neuroendocrine tumor metastases. Pancreas 2019;48:496–503. DOI: 10.1097/MPA.0000000000001271</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Xu A., Suz P., Reljic T. et al. Perioperative carcinoid crisis: a systematic review and meta-analysis. Cancers 2022;14:2966. DOI: 10.3390/cancers14122966</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Howe J.R., Merchant N.B., Conrad C. et al. The North American Neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine Tumors. Pancreas 2020;49:1–33. DOI: 10.1097/MPA.0000000000001454</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wonn S.M., Ratzlaff A.N., Pommier S.J. et al. A prospective study of carcinoid crisis with no perioperative octreotide. Surgery 2022;171:88–93. DOI: 10.1016/j.surg.2021.03.063</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Koumarianou A., Alexandraki K.I., Wallin G. et al. Pathogenesis and clinical management of mesenteric fibrosis in small intestinal neuroendocine neoplasms: a systematic review. J Clin Med 2020;9:1777.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Druce M., Rockall A., Grossman A.B. Fibrosis and carcinoid syndrome: From causation to future therapy. Nat Rev Endocrinol 2009;5:276–83. DOI: 10.1038/nrendo.2009.51</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sundin A., Arnold R., Baudin E. et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine &amp; hybrid imaging. Neuroendocrinology 2017;105:212–44. DOI: 10.1159/000471879</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Pantongrag-Brown L., Buetow P.C., Carr N.J. et al. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. Am J Roentgenol 1995;164:387–91. DOI: 10.2214/ajr.164.2.7839976</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Maasberg S., Knappe-Drzikova B., Vonderbeck D. et al. Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasia. Neuroendocrinology 2017;104:11–25. DOI: 10.1159/000442983</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pearman T.P., Beaumont J.L., Cella D. et al. Health-related quality of life in patients with neuroendocrine tumors: aninvestigation of treatment type, disease status, and symptom burden. Support Care Cancer 2016;24:3695–703. DOI: 10.1007/s00520-016-3189-z</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Laing E., Kiss N., Michael M. et al. Nutritional complications and the management of patients with gastroen teropancreatic neuroendocrine tumors. Neuroendocrinology 2020;110:430–42. DOI: 10.1159/000503634</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Marasco M., Dell’Unto E., Laviano A. et al. Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review. J Gastroenterol Hepatol 2024;39:1737–44. DOI: 10.1111/jgh.16638</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rinzivillo M., De Felice I., Magi L. et al. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. Pancreatology 2020;20:875–9. DOI: 10.1016/j.pan.2020.06.007</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Vanga R.R., Tansel A., Sidiq S. et al. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:1220–8.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Whitcomb D.C., Buchner A.M., Forsmark C.E. AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review. Gastroenterology 2023;165:1292–301. DOI: 10.1053/j.gastro.2023.07.007</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Phillips M.E. Pancreatic exocrine insufficiency following pancreatic resection. Pancreatology 2015;15:449–55. DOI: 10.1016/j.pan.2015.06.003</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Shah G.M., Shah R.G., Veillette H. et al. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol 2005;100:2307–14. DOI: 10.1111/j.1572-0241.2005.00268.x</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Bouma G., Van Faassen M., Kats-Ugurlu G. et al. Niacin (vitamin B3) supplementation in patients with serotonin-producing neuroendocrine tumor. Neuroendocrinology 2016;103:489–94. DOI: 10.1159/000440621</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Davar J., Connolly H.M., Caplin M.E. et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol 2017;69:1288–304. DOI: 10.1016/j.jacc.2016.12.030</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Jin C., Sharma A.N., Thevakumar B. et al. Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management. Cardiology 2021;146:65–73. DOI: 10.1159/000507847</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Connolly H.M., Schaff H.V., Mullany C.J. et al. Surgical management of left-sided carcinoid heart disease. Circulation 2001;104 (Suppl. S1):I36–40. DOI: 10.1161/hc37t1.094898</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Namkoong J., Andraweera P.H., Pathirana M. et al. A systematic review and meta-analysis of the diagnosis and surgical management of carcinoid heart disease. Front Cardiovasc Med 2024;11:1353612. DOI: 10.3389/fcvm.2024.1353612</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Strosberg J.R., Halfdanarson T.R., Bellizzi A.M. et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 2017;46:707–14. DOI: 10.1097/MPA.0000000000000850</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Magi, L., Mazzuca F., Rinzivillo M. et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J Clin Med 2019;8:910. DOI: 10.3390/jcm8060910</mixed-citation></ref></ref-list></back></article>
